• Tue news: Regeneron fails to block Eylea biosimilar. Inside the GLP-1 price war. Novartis inks $1B biobucks deal. UCB/Biogen lupus drug. Lilly Alzheimer’s drug approved in Japan. See more on our front page

Michel Vounatsos is on his way out as Biogen shutters Aduhelm effort and launches pipeline reorg – E


<